PBA
CRBU icon

Paradigm Biocapital Advisors’s Caribou Biosciences CRBU Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,172,620
Closed -$11.2M – 39
2024
Q1 		$11.2M Sell
2,172,620
-751,231
-26% -$4.63M 0.39% 32
2023
Q4 		$16.8M Sell
2,923,851
-20,662
-0.7% -$102K 0.78% 25
2023
Q3 		$14.1M Buy
+2,944,513
New +$18.3M 0.96% 24

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paradigm Biocapital Advisors's CRBU Position: Q2 2024 in Review

Paradigm Biocapital Advisors sold out of Caribou Biosciences (CRBU) in Q2 2024, closing a stake of 2,172,620 shares — an estimated $11.2M sold.

Paradigm Biocapital Advisors first reported a position in CRBU in Q3 2023 and held it in 3 quarters. The position peaked at $16.8M in Q4 2023. 140 funds tracked by Wall St. Rank hold CRBU as of Q2 2024.

  • Paradigm Biocapital Advisors reported no remaining Caribou Biosciences position as of Q2 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,172,620 Caribou Biosciences shares in Q2 2024, an estimated $11.2M.
  • Paradigm Biocapital Advisors first reported a position in Caribou Biosciences in Q3 2023 and held it in 3 quarters.
  • Paradigm Biocapital Advisors's Caribou Biosciences position peaked at $16.8M in Q4 2023.
  • 140 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.